Difficult ethical issues are inherent in medical research, especially clinical trials involving human subjects. Research holds the promise of finding lifesaving treatments, but it sometimes depends on the participation of vulnerable patients suffering from serious illnesses.
We at the University of Minnesota take seriously our responsibility to patients participating in clinical studies, and our critics are wrong when they assert that we have turned a blind eye to our ethical obligations ("Medical research: Honor code still needs strengthening," a May 27 commentary by U Prof. Carl Elliott).
Let me be clear about Dan Markingson's 2004 death by suicide, which is at the center of much of this conversation. The events have been the subject of many proceedings, including two reviews by the U.S. Food and Drug Administration (2005 and 2015), a lawsuit in Hennepin County District Court (2008), complaints to the Minnesota Board of Medical Practice against two doctors (2009 and 2010), and a review by the legislative auditor (2015).
As the legislative auditor concluded, we can never know if Markingson's tragic death was the result of a clinical study conducted at 26 sites, including the University of Minnesota. However, it is clear we could have done better in our response to the concerns raised about these events. I have apologized to Dan Markingson's mother, to a legislative committee and at public forums.
In addition to recognizing and respecting the personal grief of those closest to Mr. Markingson, I believe the most meaningful way for an institution to apologize to the broader Minnesota public is to be better in the future. That is what we are doing as we move forward. The university, the nation's ninth-most-active public research university, is implementing far-reaching reforms to our human subjects protection program. Our goal is to be a national model, both ethically and operationally. Last week, a faculty-led implementation team produced a 68-page action plan (http://tinyurl.com/l735b3s) to achieve this goal.
This plan reinforces our commitment to an ethical culture, minimizes conflicts of interest, creates more robust institutional review boards and oversight, and vastly improves our approach to research involving people who have impaired decisionmaking capacity.
Dr. Steven Miles, a nationally recognized University of Minnesota bioethicist and a member of the team that wrote the report, called this plan "Markingson's legacy" and said he hopes the plan will be a national model. "Having taught medical ethics now for 34 years, I think … this is possibly the most robust policy I've ever seen," he said.
I intend to implement this plan fully and with complete transparency, and I encourage you to watch us closely and judge us fairly as we do our work.